Business
Quest PharmaTech Provides Oregovomab Chemo Immunotherapy Clinical Trial and other Corporate Updates
Jun. 7, 2011 (Canada NewsWire Group) -- TSX Venture: QPT EDMONTON, AB, June 7, 2011 /CN...
About this update from Quest Pharmatech Inc.
[{"type":"text","content":"\n\n\n Jun. 7, 2011 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nTSX Venture: QPT\n\n\nEDMONTON, AB, June 7, 2011 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT)\n ("Quest" or the "Company"), a pharmaceutical company developing and\n commercializing products for the treatment of cancer, announced today\n that it conducted its first clinical Investigators Meeting for\n Oregovomab in Rome, Italy.\n\n\nOregovomab is an immunotherapeutic agent designed to trigger a specific\n immune response against CA125 expressing cancer, most notably ovarian.\n A seven center clinical trial is underway in Italy to evaluate whether\n optimally dosed Oregovomab in conjunction with front-line chemotherapy\n will generate the same or improved immune and clinical response, as\n seen in a previous Phase II clinical trial in the same patient\n population. This clinical trial is the first of three trials that the\n Company has planned to confirm Oregovomab in combination with\n front-line chemotherapy to elicit better immune and clinical responses\n in cancer patients. Successful completion of these trials will set the\n stage for a pivotal registration trial as well as proof-of-concept for\n a platform technology of chemo-enhanced immunotherapy.\n\n\nThe objective of the Investigator Meeting was to finalize the\n operational issues related to conducting a multi center clinical trial.\n The meeting was attended by investigators from all seven participating\n centers. Professor Roberto Angio...